BALPHARMA.BOBALPHARMA.BOBSE
Loading
R&D Expenses Over TimeContracting
Percentile Rank40
3Y CAGR-17.1%
5Y CAGR-2.4%
Year-over-Year Change
Research and development spending
3Y CAGR
-17.1%/yr
vs +31.6%/yr prior
5Y CAGR
-2.4%/yr
Recent deceleration
Acceleration
-48.6pp
Decelerating
Percentile
P40
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $28.07M | -13.6% |
| 2025 | $32.50M | -35.9% |
| 2024 | $50.71M | +3.1% |
| 2023 | $49.19M | +53.5% |
| 2022 | $32.04M | +0.9% |
| 2021 | $31.75M | +12.2% |
| 2020 | $28.31M | +72.5% |
| 2019 | $16.41M | -0.0% |
| 2018 | $16.41M | +11.3% |
| 2017 | $14.75M | - |